Viewing data from:

KLAYESTA

ANDA

NYSTATIN | A210532 | EPIC PHARMA LLC

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.4366

per gm

Lowest NADAC/Unit

$0.2648

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
42806018615KLAYESTA 100,000 UNIT/GM POWD	$0.4366	GM	Generic	—	2026-06-17
42806018630KLAYESTA 100,000 UNIT/GM POWD	$0.3096	GM	Generic	—	2026-06-17
42806018660KLAYESTA 100,000 UNIT/GM POWD	$0.2648	GM	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Klayesta (2024)

Total Spending

$3.1M

Total Claims

129,701

Beneficiaries

80,882

Avg Cost/Unit

$0.47

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs5 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

CENTRIENT PHARMACEUTICALS NETHERLANDS BVNYSTATIN

DMF 135231998

VUAB PHARMA ASNYSTATIN USP

DMF 140561999

ANTIBIOTICE SANYSTATIN

DMF 148132000

CONCORD BIOTECH LTDNYSTATIN USP

DMF 417912025

SHAOXING PHARMACEUTICAL FACTORYInactiveNYSTATIN

DMF 125571997

ER SQUIBB AND SONS INCInactiveNYSTATIN

DMF 132981998

BRISTOL MYERS SQUIBB COInactiveNYSTATIN

DMF 134411998

LEDERLE LABORATORIESInactiveNYSTATIN BULK POWDER

DMF 150282000

OLON SPAInactiveNYSTATIN

DMF 352252020

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 100,000 UNITS/GM

0 patents0 exclusivities▴

POWDER;TOPICAL | Approved: Apr 30, 2018

No patent or exclusivity listings for this strength.